This expansion has increased the company’s solid-phase peptide synthesis (SPPS) total reactor volume to 32,000 liters, addressing the surging global demand for peptide therapeutics.
Dr. Minzhang Chen, co-CEO of WuXi AppTec, commented: “The launch of our new peptide manufacturing plants and the development of the new Taixing site are important milestones for WuXi AppTec.
“Our expanded capacity is essential for accelerating drug development and ensuring a reliable supply chain for our global partners. WuXi AppTec will continue to focus on enhancing our capability and capacity, accelerating innovative therapies to patients globally.”
The Changzhou site has inaugurated its third peptide plant, with the other newly commissioned peptide plant situated at the company’s Taixing site.
Spanning a total area of 169 acres, the Taixing site is designed to manufacture a range of synthetic molecules, including small molecules, peptides, oligonucleotides, and conjugates.
Both new peptide plants utilize digital operation systems with automated solvent delivery, optimizing production consistency, minimizing human errors, and reducing production cycle time, the company said.
The company’s WuXi TIDES CRDMO platform provides integrated services for oligonucleotides, peptides, and conjugates, including both API and drug product from discovery to commercial stages.
With the newly expanded capacity, the platform is now poised to support more peptide therapeutic developments for global partners, WuXi added.
